Foundayo is licensed for adults meeting standard eligibility criteria — a BMI of 30+, or 27–30 with a weight-related condition — with no upper age limit built into the licensing, and its clinical trials included women across a range of ages, including postmenopausal women. Hormonal changes during perimenopause and menopause commonly contribute to weight gain and make weight loss more difficult through mechanisms including shifts in fat distribution, reduced muscle mass, and metabolic changes — a GLP-1 medicine like Foundayo doesn't target these hormonal changes directly, but it can still meaningfully support weight management alongside them. Because Foundayo only recently launched in the UK, women-specific real-world data is still emerging, though its underlying mechanism is shared with better-studied GLP-1 medicines.
The years surrounding perimenopause and menopause bring genuine physiological changes that affect weight, independent of diet and exercise habits. Declining oestrogen is associated with a shift in fat storage patterns — often toward the abdomen — and with gradual loss of muscle mass, which in turn lowers resting metabolic rate. Sleep disruption, common during this life stage, can also affect appetite-regulating hormones and energy levels in ways that make weight management harder. None of this means weight loss becomes impossible after 40, but it does mean the same approach that worked at 25 may need genuine adjustment.
How Foundayo Fits Into This PictureFoundayo works by mimicking GLP-1, a hormone that increases feelings of fullness and slows digestion — a mechanism that operates independently of the reproductive hormone changes driving midlife weight gain. This means Foundayo can help address the calorie intake side of the equation even while hormonal shifts are working against you, though it's not a treatment for menopause symptoms themselves, and it won't reverse the underlying metabolic changes menopause brings.
Worth knowing
If hot flushes, sleep disruption, mood changes or other menopause symptoms are significantly affecting your quality of life, these are worth discussing with your GP alongside any weight management plan — hormone replacement therapy (HRT) and weight management medicines like Foundayo address different things, and for many women, addressing both areas separately, rather than expecting one treatment to solve everything, produces the best overall outcome.
Foundayo's ATTAIN-1 trial, which underpins its UK weight-management licence, included adult participants across a broad age range, and GLP-1 medicines as a class have been studied extensively in postmenopausal women through other trials (including Mounjaro's and Wegovy's own trial programmes). While Foundayo-specific data broken down by menopausal status isn't yet widely published, the underlying GLP-1 mechanism has a well-established track record of effectiveness in this population through related medicines, giving reasonable confidence in how Foundayo is likely to perform, even without years of dedicated real-world data yet.
Because Foundayo only launched in the UK in August 2026, it simply hasn't had time to accumulate the same volume of real-world experience among women over 40 that more established medicines like Mounjaro and Wegovy have.
Practical Considerations Specific to This Life StageMuscle Mass Matters More
Since muscle mass naturally declines from perimenopause onward, and weight loss itself can further reduce lean mass if not actively protected, prioritising protein intake and resistance training becomes particularly important for women over 40 starting Foundayo. See our dedicated nutrition guide for specific protein targets during GLP-1 treatment.
Bone Health
Oestrogen decline during menopause is a recognised risk factor for reduced bone density, and significant weight loss by any method can further affect bone health in some circumstances. If you have risk factors for osteoporosis, this is worth raising with your prescriber before starting treatment, so it can be factored into your overall care.
Existing Health Conditions
Women over 40 are statistically more likely to be managing other health conditions — blood pressure, cholesterol, thyroid function, or early signs of type 2 diabetes — that are worth discussing openly during your consultation, since these can interact with treatment planning and, in Foundayo's case, may even be directly relevant to its separate type 2 diabetes indication.
Contraception
Important
Foundayo can reduce the absorption of oral hormonal contraceptives, which remains relevant for perimenopausal women who haven't yet reached menopause and may still be using contraception. See our dedicated Foundayo side effects guide for the specific timing windows this applies to, and discuss your contraceptive planning with your prescriber.
Women over 40 face a genuinely elevated risk of type 2 diabetes, particularly as insulin sensitivity can decline during and after menopause. Foundayo's dual UK licence — covering both weight management and improving blood sugar control in type 2 diabetes — means it's worth knowing that if you're managing both midlife weight changes and blood sugar concerns, Foundayo may be relevant to you through either or both licensed pathways. See our dedicated guide on Foundayo and type 2 diabetes for the specific evidence behind that indication.
A Note on Weight Distribution ChangesMany women notice their weight redistributing toward the abdomen during perimenopause and menopause, even without significant overall weight gain — a shift linked to declining oestrogen rather than diet or exercise habits alone. This visceral fat pattern also carries its own cardiovascular and metabolic risk profile, distinct from fat stored elsewhere on the body. While Foundayo doesn't specifically target fat in particular locations, overall weight loss through consistent treatment typically does reduce abdominal fat alongside total body weight.
Sleep and Its Knock-On EffectsSleep disruption is one of the most commonly reported challenges during perimenopause and menopause, and it has genuine knock-on effects for weight management — poor sleep is linked to increased appetite, stronger food cravings, and reduced motivation for physical activity the following day. While Foundayo doesn't directly address sleep, some people find that as appetite becomes easier to manage on treatment, the cycle of poor sleep driving overeating driving further sleep disruption becomes somewhat easier to break. If sleep problems are significant for you, it's still worth addressing this directly with your GP alongside your weight management plan, rather than expecting Foundayo alone to resolve it.
Choosing Between Foundayo and Other OptionsMounjaro and Wegovy both have several years of accumulated real-world data specifically among women over 40, including in some cases direct trial subgroup analysis by menopausal status — see our dedicated Mounjaro for women over 40 and Wegovy for women over 40 guides for that more established evidence base. Foundayo's genuine advantages, a tablet format with no fasting requirement, are worth weighing against this difference in track record. For some women, the practical convenience of a daily tablet outweighs having less accumulated real-world experience in their specific demographic; for others, the longer history behind Mounjaro or Wegovy carries more weight. Neither is the objectively correct choice — it depends on what matters most to you.
Find Out If Foundayo® Is Right For You
Foundayo® is available to order now through Happy Pharmacy. A free online consultation with our GPhC-registered pharmacy team covers your full medical history, including any menopause-related considerations.
Start Your Free Online Consultation → Happy Pharmacy is a GPhC-registered pharmacy (No. 9012585) — Superintendent Pharmacist: Palvinder Deol — Rated 4.8★ Excellent on Trustpilot- Wharton S, et al. ATTAIN-1. N Engl J Med, September 2025.
- Foundayo® (orforglipron) Summary of Product Characteristics, MHRA Products website.
- The Menopause and Weight Gain: Mechanisms and Management. British Menopause Society clinical guidance.
- NICE. Menopause: diagnosis and management (NG23).
- Foundayo® and Type 2 Diabetes: How the Dual Licence Works. Happy Pharmacy clinical guide.